Elgemtumab clinical trials
Also written LJM716.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses elgemtumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LJM716
- 5
Studies by the year they started
5 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Novartis Pharmaceuticals (4) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses elgemtumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02167854Written as LJM716
- Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)CompletedPhase 1Novartis PharmaceuticalsNCT01822613Written as LJM716
- Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric CancerCompletedPhase 1Novartis PharmaceuticalsNCT01602406Written as LJM716
- A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric CancerCompletedPhase 1Novartis PharmaceuticalsNCT01598077Written as LJM716
- Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma PatientsWithdrawnPhase 1/2Novartis PharmaceuticalsNCT02143622Written as LJM716
Codes
What other systems call elgemtumab · ClinicalTrials.gg INT000687
- MeSH (NLM) C000619694elgemtumabOne source NLM
- UNII (FDA) 5F1CN52GFMELGEMTUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q101011366elgemtumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C101895ElgemtumabOne source FDA
- DrugBank DB15430One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619694 | elgemtumab | One source NLM |
| UNII (FDA) | 5F1CN52GFM | ELGEMTUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q101011366 | elgemtumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C101895 | Elgemtumab | One source FDA |
| DrugBank | DB15430 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.